import{r as a,j as e}from"./vendor-B1DCW80S.js";import{B as L,o as N,p as C,A,q as f,r as y,s as D,t as v,I as P,E as I}from"./icons-KtW8kbC0.js";const S={Semaglutide:{name:"Semaglutide",category:"GLP-1 Agonist",status:"FDA-approved for T2D/weight loss",halfLife:"168 hours (7 days)",commonDosage:"0.25mg - 2.4mg weekly",description:"A GLP-1 receptor agonist primarily used for weight loss and blood sugar management.",benefits:["Significant weight loss (10-15% body weight)","Improved blood sugar control","Reduced appetite and food cravings","Cardiovascular benefits","Improved insulin sensitivity","Potential neuroprotective effects"],sideEffects:["Nausea (especially when starting)","Vomiting","Diarrhea or constipation","Abdominal pain","Fatigue","Headache","Dizziness"],cons:["Slow dose titration required","Injectable only; not oral","Can be expensive without insurance","GI discomfort common during escalation","Weight regain risk if stopped abruptly"],warnings:["Risk of thyroid C-cell tumors (animal studies)","Pancreatitis risk","Gallbladder problems","Kidney problems in rare cases","Not for type 1 diabetes","Contraindicated with personal/family history of medullary thyroid carcinoma"],contraindications:["Personal/family history of MTC","MEN2","History of pancreatitis without clearance","Pregnancy or breastfeeding"],protocols:[{name:"Standard Weight Loss Protocol",level:"Beginner to Advanced",description:"FDA-approved escalation schedule for weight management",schedule:[{week:"1-4",dose:"0.25mg",frequency:"Once weekly",notes:"Titration phase - minimize side effects"},{week:"5-8",dose:"0.5mg",frequency:"Once weekly",notes:"Continue if tolerating well"},{week:"9-12",dose:"1mg",frequency:"Once weekly",notes:"Therapeutic dose for many users"},{week:"13-16",dose:"1.7mg",frequency:"Once weekly",notes:"Optional escalation"},{week:"17+",dose:"2.4mg",frequency:"Once weekly",notes:"Maximum dose"}],duration:"16-20 weeks minimum",notes:"Stay at each dose for at least 4 weeks. Only increase if weight loss plateaus and side effects are minimal."},{name:"Maintenance Protocol",level:"Maintenance",description:"After reaching goal weight",schedule:[{week:"Ongoing",dose:"0.5-1mg",frequency:"Once weekly",notes:"Lowest effective dose"}],duration:"Long-term",notes:"Find minimum dose that maintains weight loss. Some users cycle off for 4-8 weeks periodically."}],administration:"Subcutaneous injection once weekly",storage:"Refrigerate before reconstitution. After reconstitution, use within 56 days.",researchLinks:["https://www.nejm.org/doi/full/10.1056/NEJMoa2032183","https://pubmed.ncbi.nlm.nih.gov/33567185/"]},Tirzepatide:{name:"Tirzepatide",category:"Dual GIP/GLP-1 Agonist",status:"FDA-approved for T2D; weight loss pending regions",halfLife:"120 hours (5 days)",commonDosage:"2.5mg - 15mg weekly",description:"A dual GIP and GLP-1 receptor agonist showing superior weight loss compared to semaglutide.",benefits:["Superior weight loss (15-22% body weight)","Excellent blood sugar control","Improved lipid profiles","Reduced cardiovascular risk","Better appetite suppression than GLP-1 alone","Improved insulin sensitivity"],sideEffects:["Nausea and vomiting","Diarrhea","Decreased appetite","Constipation","Indigestion","Fatigue"],cons:["Significant GI side effects during titration","Higher cost than most GLP-1s","Injectable only","Limited long-term cardiovascular data","Potential hypoglycemia when combined with insulin"],warnings:["Similar thyroid tumor risk as semaglutide","Pancreatitis risk","Hypoglycemia when combined with insulin","Gallbladder disease","Acute kidney injury in dehydrated patients"],contraindications:["Personal/family history of MTC or MEN2","History of pancreatitis without clearance","Pregnancy or breastfeeding"],protocols:[{name:"Escalation Protocol",level:"Beginner",description:"Standard FDA titration",schedule:[{week:"1-4",dose:"2.5mg",frequency:"Once weekly",notes:"Starter dose"},{week:"5-8",dose:"5mg",frequency:"Once weekly"},{week:"9-12",dose:"7.5-10mg",frequency:"Once weekly",notes:"Advance if tolerated"},{week:"13+",dose:"12.5-15mg",frequency:"Once weekly",notes:"Max dose"}],duration:"Ongoing",notes:"Hold dose increases if GI effects persist."}],administration:"Subcutaneous injection once weekly",storage:"Refrigerate. Protect from light.",researchLinks:["https://www.nejm.org/doi/full/10.1056/NEJMoa2107519"]},Liraglutide:{name:"Liraglutide",category:"GLP-1 Agonist",status:"FDA-approved for T2D/weight loss",halfLife:"13 hours",commonDosage:"0.6mg - 3.0mg daily",description:"Daily GLP-1 analog used for diabetes and chronic weight management.",benefits:["Weight loss and appetite control","Improved glycemic control","Cardiovascular risk reduction","Daily dosing allows quick titration changes"],sideEffects:["Nausea","Vomiting","Diarrhea or constipation","Injection site pain"],cons:["Requires daily injections","GI side effects common early","Less weight loss than weekly GLP-1s","Costs can be high without coverage"],warnings:["Thyroid C-cell tumor warning","Pancreatitis risk","Gallbladder disease"],contraindications:["Personal/family history of MTC or MEN2","History of pancreatitis without clearance","Pregnancy or breastfeeding"],protocols:[{name:"Weight Management Titration",level:"Beginner",description:"Standard Saxenda titration",schedule:[{week:"1",dose:"0.6mg",frequency:"Daily"},{week:"2",dose:"1.2mg",frequency:"Daily"},{week:"3",dose:"1.8mg",frequency:"Daily"},{week:"4",dose:"2.4mg",frequency:"Daily"},{week:"5+",dose:"3.0mg",frequency:"Daily",notes:"Maintenance/max"}],duration:"Ongoing",notes:"Hold or reduce dose if GI side effects persist."}],administration:"Subcutaneous injection once daily",storage:"Refrigerate unopened. After first use, may keep at room temp for 30 days.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/20573918/"]},Dulaglutide:{name:"Dulaglutide",category:"GLP-1 Agonist",status:"FDA-approved for T2D",halfLife:"120 hours (5 days)",commonDosage:"0.75mg - 4.5mg weekly",description:"Once-weekly GLP-1 analog used for glycemic control with modest weight loss.",benefits:["Improved glycemic control","Cardiovascular risk reduction data","Convenient weekly dosing"],sideEffects:["Nausea","Diarrhea","Vomiting","Abdominal pain"],cons:["Less weight loss than newer GLP-1s","GI side effects during titration","Not indicated for obesity alone in some regions"],warnings:["Thyroid C-cell tumor warning","Pancreatitis risk","Gallbladder disease"],contraindications:["Personal/family history of MTC or MEN2","History of pancreatitis without clearance","Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection once weekly",storage:"Refrigerate. Do not freeze.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/24550040/"]},Retatrutide:{name:"Retatrutide",category:"Triple Agonist (GLP-1/GIP/Glucagon)",status:"Investigational",halfLife:"Approx. 5-7 days (investigational)",commonDosage:"1-12mg weekly (trial ranges)",description:"Triple incretin/agonist in trials showing substantial weight loss.",benefits:["Very high weight loss in trials","Multi-pathway metabolic effects","Weekly dosing"],sideEffects:["GI effects similar to GLP-1s","Potential heart rate increase","Injection site reactions"],cons:["Investigational; limited safety data","Potential glucagon-related side effects","Dosing not standardized","Access limited to trials"],warnings:["Pancreatitis risk theoretical","May affect heart rate","Thyroid C-cell tumor warning anticipated"],contraindications:["Outside clinical trials","Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection once weekly (trial protocol)",storage:"Refrigerate; follow trial protocol.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/37397207/"]},"BPC-157":{name:"BPC-157",category:"Healing Peptide",status:"Research chemical",halfLife:"4 hours",commonDosage:"250-500mcg daily",description:"A synthetic peptide derived from a protective protein found in stomach acid, known for healing properties.",benefits:["Accelerated wound healing","Tendon and ligament repair","Muscle healing","Gut healing (leaky gut, IBS)","Reduced inflammation","Joint pain relief","Neuroprotective effects","Improved blood flow"],sideEffects:["Generally well-tolerated","Occasional fatigue","Dizziness (rare)","Nausea (rare)","Headache (rare)"],cons:["Human clinical data is limited","Quality/purity varies by vendor","Requires frequent injections","Regulatory status is unclear in many regions"],warnings:["Limited human clinical trials","Long-term safety unknown","May affect blood pressure","Consult doctor if on blood thinners"],contraindications:["Pregnancy or breastfeeding","Uncontrolled hypertension"],protocols:[],administration:"Subcutaneous or intramuscular injection, 1-2 times daily",storage:"Refrigerate after reconstitution. Use within 30 days.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/31633635/","https://pubmed.ncbi.nlm.nih.gov/32568251/"]},"TB-500":{name:"TB-500 (Thymosin Beta-4)",category:"Healing Peptide",status:"Research chemical; WADA banned",halfLife:"120 hours (5 days)",commonDosage:"2-5mg twice weekly",description:"A synthetic version of Thymosin Beta-4, promoting healing and recovery.",benefits:["Enhanced tissue repair","Reduced inflammation","Improved flexibility","Faster injury recovery","Hair growth promotion","Cardiovascular protection","Neuroprotection"],sideEffects:["Minimal side effects reported","Possible headache","Lethargy","Temporary flushing"],cons:["Banned by many sports organizations","Relatively expensive for full cycles","Often paired with other peptides to see results","Limited long-term human research"],warnings:["Banned by WADA for athletes","Limited long-term human studies","May promote cancer cell migration (theoretical)","Avoid if pregnant or breastfeeding"],contraindications:["Competitive athletes subject to testing","Pregnancy or breastfeeding","Active malignancy"],protocols:[],administration:"Subcutaneous or intramuscular injection",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/20709819/"]},Ipamorelin:{name:"Ipamorelin",category:"Growth Hormone Secretagogue",status:"Research chemical",halfLife:"2 hours",commonDosage:"200-300mcg 2-3 times daily",description:"A selective growth hormone secretagogue that stimulates GH release without affecting cortisol.",benefits:["Increased growth hormone production","Improved muscle mass","Enhanced fat loss","Better sleep quality","Improved skin elasticity","Faster recovery","Increased bone density","Anti-aging effects"],sideEffects:["Water retention (mild)","Increased hunger","Tingling or numbness","Headache","Flushing"],cons:["Multiple daily injections required","Water retention and hunger can be bothersome","Cost adds up over long cycles","Timing around meals/workouts matters for consistency"],warnings:["May affect blood sugar levels","Not for use with active cancer","Consult doctor if diabetic","May interact with thyroid medications"],contraindications:["Active malignancy","Uncontrolled diabetes","Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection, typically before bed or post-workout",storage:"Refrigerate after reconstitution. Use within 30 days.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/9849822/"]},"CJC-1295 (no DAC)":{name:"CJC-1295 (no DAC)",category:"Growth Hormone Releasing Hormone",status:"Research chemical",halfLife:"0.5 hours (30 minutes)",commonDosage:"100-200mcg 2-3 times daily",description:"A GHRH analog that increases growth hormone and IGF-1 levels with short half-life.",benefits:["Increased GH and IGF-1 levels","Muscle growth","Fat loss","Improved recovery","Better sleep","Enhanced immune function","Increased bone density"],sideEffects:["Water retention","Joint pain","Carpal tunnel symptoms","Increased hunger","Numbness or tingling"],cons:["Very short half-life demands multiple daily injections","May raise blood sugar temporarily","Less convenient compared to DAC version","Often needs stacking (e.g., Ipamorelin) for best effect"],warnings:["May worsen existing tumors","Affects blood sugar","Not for pregnant/nursing women","Regular blood work recommended"],contraindications:["Active malignancy","Uncontrolled diabetes","Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection, often combined with Ipamorelin",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/16352683/"]},"CJC-1295 (DAC)":{name:"CJC-1295 (DAC)",category:"Growth Hormone Releasing Hormone",status:"Research chemical",halfLife:"168 hours (7 days)",commonDosage:"1-2mg once weekly",description:"Long-acting GHRH analog with drug affinity complex (DAC) for extended half-life.",benefits:["Sustained GH and IGF-1 elevation","Reduced injection frequency","Supports muscle gain and fat loss","Improved sleep quality","Potential immune support"],sideEffects:["Water retention","Flu-like symptoms (rare)","Joint stiffness","Injection site irritation"],cons:["More expensive than no-DAC version","Long half-life makes dose adjustments slower","Potential for prolonged side effects","Still off-label with limited human data"],warnings:["May worsen existing tumors","Monitor blood glucose and IGF-1","Not recommended during pregnancy","Use medical supervision for long protocols"],contraindications:["Active malignancy","Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection once weekly",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/16352683/"]},"MK-677 (Ibutamoren)":{name:"MK-677 (Ibutamoren)",category:"Growth Hormone Secretagogue",status:"Research chemical",halfLife:"24 hours",commonDosage:"10-25mg orally daily",description:"An oral ghrelin mimetic that increases GH and IGF-1 without injections.",benefits:["Oral dosing convenience","Increased GH/IGF-1 levels","Improved sleep depth","Appetite stimulation","Potential muscle gain and fat loss support"],sideEffects:["Water retention","Increased appetite","Numbness/tingling","Transient insulin resistance","Lethargy in some users"],cons:["Can raise fasting glucose and insulin","Not ideal for those managing appetite/weight loss","Edema and carpal tunnel-like symptoms possible","Long half-life makes side effects linger"],warnings:["Monitor glucose and lipids","Avoid in active cancer","Not for pregnancy or nursing","Use caution with diabetes or insulin resistance"],contraindications:["Active malignancy","Uncontrolled diabetes","Pregnancy or breastfeeding"],protocols:[],administration:"Oral capsule or liquid, once daily",storage:"Store in a cool, dry place away from light.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/9430604/"]},"Melanotan II":{name:"Melanotan II",category:"Melanocortin Agonist",status:"Research chemical",halfLife:"1 hour",commonDosage:"0.25-1mg daily",description:"A synthetic analog of alpha-melanocyte stimulating hormone, used for tanning and libido enhancement.",benefits:["Skin tanning without UV exposure","Increased libido","Potential appetite suppression","Erectile function improvement","Reduced sun damage risk"],sideEffects:["Nausea (common initially)","Flushing","Increased libido (can be unwanted)","Darkening of moles and freckles","Yawning and stretching","Spontaneous erections"],cons:["Nausea and flushing can be intense early on","Can permanently darken moles/freckles","Not FDA approved; quality varies","Cosmetic focus with limited safety data"],warnings:["Not FDA approved","May increase melanoma risk (theoretical)","Can darken existing moles","Permanent skin darkening possible","Cardiovascular effects possible"],contraindications:["Personal or family melanoma history","Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection, typically in evening",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/16448591/"]},"PT-141 (Bremelanotide)":{name:"PT-141 (Bremelanotide)",category:"Melanocortin Agonist",status:"FDA-approved nasal for HSDD; injectable research use",halfLife:"2.5 hours",commonDosage:"1.25-1.75mg as needed",description:"A melanocortin receptor agonist for sexual dysfunction in men and women.",benefits:["Improves libido in both sexes","Works independent of nitric oxide pathways","Rapid onset (within 30-60 minutes)","FDA-approved nasal form for female HSDD"],sideEffects:["Nausea","Flushing","Headache","Transient blood pressure changes","Injection site irritation"],cons:["Effects are short-lived","Can cause pronounced nausea","May temporarily raise blood pressure","Cost can be high per dose"],warnings:["Avoid with uncontrolled hypertension","Not for pregnancy","Use caution with cardiovascular disease","Nasal formulation has specific dosing limits"],contraindications:["Uncontrolled hypertension","Cardiovascular disease without clearance","Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection 30-60 minutes before activity",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/16034475/"]},"GHK-Cu":{name:"GHK-Cu (Copper Peptide)",category:"Healing & Anti-Aging",status:"Cosmeceutical/research",halfLife:"1 hour",commonDosage:"1-3mg 2-3 times weekly",description:"A naturally occurring copper complex with powerful healing and anti-aging properties.",benefits:["Wound healing acceleration","Collagen and elastin production","Skin rejuvenation","Hair growth stimulation","Anti-inflammatory effects","Antioxidant properties","Improved skin firmness","Reduced fine lines and wrinkles"],sideEffects:["Minimal side effects","Possible skin irritation (topical)","Mild headache (rare)","Temporary redness at injection site"],cons:["Short stability once reconstituted","Topical use can stain fabrics","Limited systemic human data","Costs increase for cosmetic use over time"],warnings:["Avoid if allergic to copper","May interact with copper supplements","Limited long-term studies","Consult doctor if on blood thinners"],contraindications:["Copper allergy","Pregnancy or breastfeeding (systemic use)"],protocols:[],administration:"Subcutaneous injection or topical application",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/25607907/","https://pubmed.ncbi.nlm.nih.gov/28294172/"]},"AOD-9604":{name:"AOD-9604",category:"Metabolic & Fat Loss",status:"Research chemical",halfLife:"2-3 hours",commonDosage:"250-500mcg daily",description:"A modified fragment of human growth hormone designed to promote fat loss without GH-related effects.",benefits:["May enhance fat oxidation","Minimal impact on blood sugar","No significant effect on IGF-1","Generally mild side effect profile"],sideEffects:["Headache (rare)","Mild nausea","Injection site redness"],cons:["Human data is limited and mixed","Fat loss effects can be modest","Requires daily injections","Not FDA approved for obesity"],warnings:["Limited clinical validation","Avoid during pregnancy or nursing","Monitor for unexpected glucose changes"],contraindications:["Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection once daily",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/21869961/"]},"MOTS-c":{name:"MOTS-c",category:"Metabolic & Mitochondrial",status:"Research chemical",halfLife:"2-4 hours",commonDosage:"10-20mg weekly (split doses)",description:"A mitochondrial-derived peptide studied for metabolic regulation and exercise performance.",benefits:["Improves insulin sensitivity (animal data)","Supports mitochondrial function","May enhance exercise performance","Potential anti-inflammatory effects"],sideEffects:["Limited human data; side effects largely unknown","Mild fatigue reported anecdotally","Injection site irritation"],cons:["Very limited human research","Dosing protocols are not standardized","Expensive due to production complexity","Unclear long-term safety"],warnings:["Use caution with metabolic disorders until more data emerges","Avoid during pregnancy","Monitor glucose if combining with other metabolic agents"],contraindications:["Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection 2-3 times per week",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/25622254/"]},Selank:{name:"Selank",category:"Cognitive & Anxiolytic",status:"Research; approved regionally (Russia)",halfLife:"0.5-1 hour",commonDosage:"250-750mcg 1-3 times daily (nasal or subcutaneous)",description:"An anxiolytic peptide derived from tuftsin, studied for calming and cognitive effects.",benefits:["Reduces anxiety without sedation (anecdotal)","May improve focus and memory","Supports immune modulation","Low risk of dependence"],sideEffects:["Mild nasal irritation (if intranasal)","Headache","Fatigue in some users"],cons:["Short half-life requires frequent dosing","Evidence primarily from small studies","Effects can be subtle or subjective","Not FDA approved"],warnings:["Limited long-term human data","Avoid use in pregnancy","Monitor for mood changes when combined with other nootropics"],contraindications:["Pregnancy or breastfeeding"],protocols:[],administration:"Intranasal spray or subcutaneous injection multiple times daily",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/15862908/"]},Semax:{name:"Semax",category:"Cognitive & Nootropic",status:"Research; approved regionally (Russia)",halfLife:"0.5-1 hour",commonDosage:"200-600mcg 1-3 times daily (nasal)",description:"A synthetic ACTH(4-10) analog used in Russia for cognitive support and neuroprotection.",benefits:["May enhance focus and memory","Neuroprotective properties (animal data)","Potential mood stabilization","Low systemic side effect burden"],sideEffects:["Nasal irritation","Headache","Transient blood pressure increase (rare)"],cons:["Requires multiple daily doses","Clinical data is region-specific and limited","Subjective effects vary widely","Not approved in most countries"],warnings:["Avoid during pregnancy","Use caution with uncontrolled hypertension","Limited long-term safety data"],contraindications:["Pregnancy or breastfeeding","Uncontrolled hypertension"],protocols:[],administration:"Intranasal spray divided through the day",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/9855565/"]},"Thymosin Alpha-1":{name:"Thymosin Alpha-1",category:"Immune Modulator",status:"Investigational/adjunctive",halfLife:"2 hours",commonDosage:"1.6mg 2-3 times weekly",description:"Synthetic thymic peptide explored for immune modulation and antiviral support.",benefits:["Supports immune response","Adjunct in some infections (regional use)","May aid vaccine response"],sideEffects:["Injection site redness","Fatigue","Mild headache"],cons:["Access varies by region","Limited robust RCTs in many indications","Cost for long courses"],warnings:["Use under medical supervision","Potential autoimmune considerations"],contraindications:["Pregnancy or breastfeeding","Autoimmune disease without clearance"],protocols:[],administration:"Subcutaneous injection several times per week",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/31445021/"]},Epithalon:{name:"Epithalon",category:"Longevity & Telomerase",status:"Research chemical",halfLife:"20 minutes (plasma)",commonDosage:"5-10mg daily (short courses)",description:"Tetrapeptide researched for potential telomerase activation and longevity effects.",benefits:["Potential telomerase activation (animal data)","Sleep quality improvements (anecdotal)","Antioxidant activity"],sideEffects:["Limited human data; generally mild","Injection site irritation","Occasional vivid dreams"],cons:["Human evidence limited","Short half-life requires daily dosing","Regulatory status unclear"],warnings:["Long-term safety unknown","Use caution with hormone-sensitive conditions"],contraindications:["Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection daily for 10-20 days (cycles)",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/15123323/"]},"SS-31 (Elamipretide)":{name:"SS-31 (Elamipretide)",category:"Mitochondrial Peptide",status:"Investigational",halfLife:"1-2 hours",commonDosage:"5-10mg daily (trial-dependent)",description:"A mitochondria-targeted peptide being studied for cardiomyopathy and mitochondrial disorders.",benefits:["May improve mitochondrial function","Potential cardiac protective effects","Explored in ophthalmic formulations"],sideEffects:["Injection site reactions","Headache","Nausea"],cons:["Investigational; limited access","Costly outside trials","Long-term safety unknown"],warnings:["Use only under research/clinical supervision"],contraindications:["Use outside approved trials"],protocols:[],administration:"Subcutaneous injection daily (per protocol)",storage:"Refrigerate; protect from light.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/21465260/"]},Cerebrolysin:{name:"Cerebrolysin",category:"Neuropeptide Blend",status:"Approved in some countries; research elsewhere",halfLife:"Variable (peptide mixture)",commonDosage:"5-10ml IV/IM daily (cycles)",description:"A porcine brain-derived peptide mixture used in some regions for cognitive and stroke recovery support.",benefits:["Neuroprotective properties","Potential cognitive support","May aid stroke recovery"],sideEffects:["Injection site pain","Dizziness","Headache"],cons:["IV/IM administration required","Variable evidence across indications","Access and regulatory status differ by country"],warnings:["Avoid in seizure disorders without clearance","Use medical supervision for IV/IM"],contraindications:["History of epilepsy without clearance","Pregnancy or breastfeeding"],protocols:[],administration:"Intramuscular or intravenous injection in cycles (e.g., 10-20 days)",storage:"Store at controlled room temperature; avoid freezing.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/25644553/"]},P21:{name:"P21",category:"Nootropic Peptide",status:"Research chemical",halfLife:"Not well established",commonDosage:"5-10mg weekly (anecdotal)",description:"A synthetic peptide derived from CNTF fragments, explored for neurotrophic effects.",benefits:["Potential neurotrophic support (preclinical)","May aid cognitive function (anecdotal)"],sideEffects:["Limited data; unknown long-term safety","Injection site irritation"],cons:["Very limited research","Dosing is anecdotal","Quality control concerns in market"],warnings:["Research-only; insufficient human safety data"],contraindications:["Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection (research use)",storage:"Refrigerate after reconstitution.",researchLinks:[]},"Follistatin 344":{name:"Follistatin 344",category:"Performance & Muscle",status:"Research chemical; WADA banned",halfLife:"6-12 hours",commonDosage:"100-300mcg daily (short bursts)",description:"A myostatin-binding protein fragment explored for muscle growth and recovery.",benefits:["Potential increase in muscle mass","Supports recovery","May enhance strength gains","Synergistic with resistance training"],sideEffects:["Injection site irritation","Possible GI discomfort","Unknown endocrine effects"],cons:["Human data is sparse and mostly experimental","Expensive and often under-dosed commercially","Short cycles make consistency hard","Potential for disproportionate muscle-tendon adaptation"],warnings:["Not approved for human use","Potential impact on fertility and hormones unknown","Avoid if pregnant or breastfeeding"],contraindications:["Competitive athletes (banned substance)","Pregnancy or breastfeeding"],protocols:[],administration:"Subcutaneous injection daily for short cycles (2-4 weeks)",storage:"Refrigerate after reconstitution.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/15345781/"]},"YK-11":{name:"YK-11",category:"Performance & Muscle",status:"Research chemical; SARM-like",halfLife:"6-10 hours (est.)",commonDosage:"5-15mg orally daily",description:"A myostatin-inhibiting SARM-like compound promoted for muscle growth.",benefits:["Potential rapid strength gains","May inhibit myostatin pathways","Oral dosing convenience"],sideEffects:["Joint pain","Liver strain potential","Hair shedding (androgenic)","Aggression or mood changes"],cons:["Very limited human safety data","Potential liver toxicity; requires labs","Often mislabeled or impure in market","Not a true peptide; regulatory risk is high"],warnings:["Hepatotoxicity riskâ€”monitor liver enzymes","Not for women who are pregnant or breastfeeding","Prohormone/PCT considerations not well-studied"],contraindications:["Liver disease","Pregnancy or breastfeeding"],protocols:[],administration:"Oral capsules or liquid, once daily",storage:"Store in a cool, dry place away from light.",researchLinks:["https://pubmed.ncbi.nlm.nih.gov/23118235/"]}},M="_container_hmv8c_7",R="_hero_hmv8c_14",E="_heroIcon_hmv8c_26",H="_eyebrow_hmv8c_38",T="_title_hmv8c_47",G="_subtitle_hmv8c_56",F="_heroStats_hmv8c_62",B="_stat_hmv8c_68",q="_controls_hmv8c_89",O="_search_hmv8c_97",z="_filter_hmv8c_98",U="_filterResult_hmv8c_123",W="_dot_hmv8c_136",V="_layout_hmv8c_143",J="_peptideGrid_hmv8c_149",K="_peptideCard_hmv8c_155",$="_activeCard_hmv8c_173",Y="_cardHeader_hmv8c_179",Q="_cardCategory_hmv8c_186",X="_cardDescription_hmv8c_198",Z="_cardMeta_hmv8c_204",ee="_tags_hmv8c_217",ie="_detailColumn_hmv8c_233",ne="_detailCard_hmv8c_239",te="_detailHeader_hmv8c_245",se="_pills_hmv8c_258",ae="_detailDescription_hmv8c_277",oe="_detailMeta_hmv8c_282",re="_label_hmv8c_300",ce="_columns_hmv8c_308",le="_benefitsBlock_hmv8c_330",de="_sideEffectsBlock_hmv8c_336",me="_consBlock_hmv8c_342",he="_warningsBlock_hmv8c_348",ue="_protocols_hmv8c_354",ge="_protocolHeader_hmv8c_358",pe="_protocolList_hmv8c_370",fe="_protocolCard_hmv8c_375",ye="_protocolTitle_hmv8c_382",ve="_protocolDuration_hmv8c_394",be="_protocolDescription_hmv8c_400",we="_schedule_hmv8c_405",je="_scheduleItem_hmv8c_410",ke="_scheduleWeek_hmv8c_420",xe="_scheduleDose_hmv8c_425",_e="_scheduleFrequency_hmv8c_430",Le="_scheduleNotes_hmv8c_435",Ne="_protocolNotes_hmv8c_440",Ce="_research_hmv8c_446",Ae="_researchHeader_hmv8c_450",De="_researchList_hmv8c_457",Pe="_researchLink_hmv8c_462",Ie="_callout_hmv8c_474",Se="_calloutTitle_hmv8c_484",Me="_calloutBody_hmv8c_489",i={container:M,hero:R,heroIcon:E,eyebrow:H,title:T,subtitle:G,heroStats:F,stat:B,controls:q,search:O,filter:z,filterResult:U,dot:W,layout:V,peptideGrid:J,peptideCard:K,activeCard:$,cardHeader:Y,cardCategory:Q,cardDescription:X,cardMeta:Z,tags:ee,detailColumn:ie,detailCard:ne,detailHeader:te,pills:se,detailDescription:ae,detailMeta:oe,label:re,columns:ce,benefitsBlock:le,sideEffectsBlock:de,consBlock:me,warningsBlock:he,protocols:ue,protocolHeader:ge,protocolList:pe,protocolCard:fe,protocolTitle:ye,protocolDuration:ve,protocolDescription:be,schedule:we,scheduleItem:je,scheduleWeek:ke,scheduleDose:xe,scheduleFrequency:_e,scheduleNotes:Le,protocolNotes:Ne,research:Ce,researchHeader:Ae,researchList:De,researchLink:Pe,callout:Ie,calloutTitle:Se,calloutBody:Me},Re=()=>{const o=a.useMemo(()=>Object.values(S),[]),h=a.useMemo(()=>["All",...new Set(o.map(n=>n.category))],[o]),[l,b]=a.useState(""),[c,w]=a.useState("All"),[t,u]=a.useState(o[0]),d=a.useRef(null),g=a.useRef(!1),r=a.useMemo(()=>{const n=l.toLowerCase();return o.filter(s=>{const x=s.name.toLowerCase().includes(n)||s.description.toLowerCase().includes(n)||s.category.toLowerCase().includes(n),_=c==="All"||s.category===c;return x&&_})},[c,o,l]);a.useEffect(()=>{if(!r.length)return;r.find(s=>s.name===t?.name)||u(r[0])},[r,t]);const j=a.useMemo(()=>o.reduce((n,s)=>n+(s.researchLinks?.length||0),0),[o]),m=t?.protocols||[],p=t?.cons||[],k=n=>{g.current=!0,u(n)};return a.useEffect(()=>{d.current&&g.current&&(typeof window<"u"&&window.innerWidth>900||d.current.scrollIntoView({behavior:"smooth",block:"start"}))},[t]),e.jsxs("div",{className:i.container,children:[e.jsxs("section",{className:i.hero,children:[e.jsx("div",{className:i.heroIcon,children:e.jsx(L,{size:32})}),e.jsxs("div",{children:[e.jsx("p",{className:i.eyebrow,children:"Reference"}),e.jsx("h1",{className:i.title,children:"Peptide Encyclopedia"}),e.jsx("p",{className:i.subtitle,children:"Fast lookups for half-life, dosing ranges, benefits, risks, and research links."})]}),e.jsxs("div",{className:i.heroStats,children:[e.jsxs("div",{className:i.stat,children:[e.jsx("span",{children:"Total peptides"}),e.jsx("strong",{children:o.length})]}),e.jsxs("div",{className:i.stat,children:[e.jsx("span",{children:"Categories"}),e.jsx("strong",{children:h.length-1})]}),e.jsxs("div",{className:i.stat,children:[e.jsx("span",{children:"Research links"}),e.jsx("strong",{children:j})]})]})]}),e.jsxs("div",{className:i.controls,children:[e.jsxs("div",{className:i.search,children:[e.jsx(N,{size:18}),e.jsx("input",{type:"text",placeholder:"Search by name, use-case, or category...",value:l,onChange:n=>b(n.target.value),"aria-label":"Search peptides"})]}),e.jsxs("div",{className:i.filter,children:[e.jsx(C,{size:18}),e.jsx("select",{value:c,onChange:n=>w(n.target.value),"aria-label":"Filter by category",children:h.map(n=>e.jsx("option",{value:n,children:n},n))})]}),e.jsxs("div",{className:i.filterResult,children:[e.jsxs("span",{children:[r.length," peptides"]}),e.jsx("span",{className:i.dot}),e.jsx("span",{children:"click a card to inspect"})]})]}),e.jsxs("div",{className:i.layout,children:[e.jsx("div",{className:i.listColumn,children:e.jsx("div",{className:i.peptideGrid,children:r.map(n=>e.jsxs("button",{className:`${i.peptideCard} ${t?.name===n.name?i.activeCard:""}`,onClick:()=>k(n),children:[e.jsxs("div",{className:i.cardHeader,children:[e.jsxs("div",{children:[e.jsx("p",{className:i.cardCategory,children:n.category}),e.jsx("h3",{children:n.name})]}),e.jsx(A,{size:18})]}),e.jsx("p",{className:i.cardDescription,children:n.description}),e.jsxs("div",{className:i.cardMeta,children:[e.jsxs("span",{children:[e.jsx(f,{size:16}),n.halfLife]}),e.jsxs("span",{children:[e.jsx(y,{size:16}),n.commonDosage]})]}),e.jsx("div",{className:i.tags,children:(n.benefits||[]).slice(0,3).map(s=>e.jsx("span",{children:s},s))})]},n.name))})}),t&&e.jsx("div",{className:i.detailColumn,ref:d,children:e.jsxs("div",{className:`glass-panel ${i.detailCard}`,children:[e.jsxs("div",{className:i.detailHeader,children:[e.jsxs("div",{children:[e.jsx("p",{className:i.cardCategory,children:t.category}),e.jsx("h2",{children:t.name})]}),e.jsxs("div",{className:i.pills,children:[e.jsxs("span",{children:[e.jsx(f,{size:16}),t.halfLife]}),e.jsxs("span",{children:[e.jsx(y,{size:16}),t.commonDosage]})]})]}),e.jsx("p",{className:i.detailDescription,children:t.description}),e.jsxs("div",{className:i.detailMeta,children:[e.jsxs("div",{children:[e.jsx(D,{size:18}),e.jsxs("div",{children:[e.jsx("p",{className:i.label,children:"Administration"}),e.jsx("p",{children:t.administration})]})]}),e.jsxs("div",{children:[e.jsx(v,{size:18}),e.jsxs("div",{children:[e.jsx("p",{className:i.label,children:"Storage"}),e.jsx("p",{children:t.storage})]})]})]}),e.jsxs("div",{className:i.columns,children:[e.jsxs("div",{className:i.benefitsBlock,children:[e.jsx("p",{className:i.label,children:"Benefits"}),e.jsx("ul",{children:(t.benefits||[]).map(n=>e.jsx("li",{children:n},n))})]}),e.jsxs("div",{className:i.sideEffectsBlock,children:[e.jsx("p",{className:i.label,children:"Side Effects"}),e.jsx("ul",{children:(t.sideEffects||[]).map(n=>e.jsx("li",{children:n},n))})]}),e.jsxs("div",{className:i.consBlock,children:[e.jsx("p",{className:i.label,children:"Cons"}),e.jsx("ul",{children:p.length>0?p.map(n=>e.jsx("li",{children:n},n)):e.jsx("li",{children:"No major cons listed."})})]}),e.jsxs("div",{className:i.warningsBlock,children:[e.jsx("p",{className:i.label,children:"Warnings"}),e.jsx("ul",{children:(t.warnings||[]).map(n=>e.jsx("li",{children:n},n))})]})]}),m.length>0&&e.jsxs("div",{className:i.protocols,children:[e.jsxs("div",{className:i.protocolHeader,children:[e.jsx("h4",{children:"Protocols"}),e.jsxs("span",{children:[m.length," available"]})]}),e.jsx("div",{className:i.protocolList,children:m.map(n=>e.jsxs("div",{className:i.protocolCard,children:[e.jsxs("div",{className:i.protocolTitle,children:[e.jsxs("div",{children:[e.jsx("p",{className:i.cardCategory,children:n.level}),e.jsx("h5",{children:n.name})]}),e.jsx("p",{className:i.protocolDuration,children:n.duration})]}),e.jsx("p",{className:i.protocolDescription,children:n.description}),e.jsx("div",{className:i.schedule,children:n.schedule.map(s=>e.jsxs("div",{className:i.scheduleItem,children:[e.jsx("div",{className:i.scheduleWeek,children:s.week}),e.jsxs("div",{className:i.scheduleDetails,children:[e.jsx("p",{className:i.scheduleDose,children:s.dose}),e.jsx("p",{className:i.scheduleFrequency,children:s.frequency}),s.notes&&e.jsx("p",{className:i.scheduleNotes,children:s.notes})]})]},`${n.name}-${s.week}`))}),n.notes&&e.jsx("p",{className:i.protocolNotes,children:n.notes})]},n.name))})]}),e.jsxs("div",{className:i.research,children:[e.jsxs("div",{className:i.researchHeader,children:[e.jsx("h4",{children:"Research Links"}),e.jsx(P,{size:16})]}),e.jsx("div",{className:i.researchList,children:(t.researchLinks||[]).map(n=>e.jsxs("a",{href:n,target:"_blank",rel:"noopener noreferrer",className:i.researchLink,children:[e.jsx(I,{size:14}),n]},n))})]}),e.jsxs("div",{className:i.callout,children:[e.jsx(v,{size:18}),e.jsxs("div",{children:[e.jsx("p",{className:i.calloutTitle,children:"For research reference only"}),e.jsx("p",{className:i.calloutBody,children:"Consult medical guidance before use. This library summarizes published data and common protocols, and is not a substitute for professional advice."})]})]})]})})]})]})},Te=()=>e.jsx(Re,{});export{Te as default};
